Protara Q2 net loss $12.8M; cash $145M; on track for TARA-002 IND by year-end

Protara Therapeutics, Inc.

2022-Q2 EPS reported -$2.34

Cash $145M; net loss $12.8M ($1.14/sh) vs $7.1M ($1.22/sh) in Q2 2020.
R&D expense rose to $5.9M (from $2.5M) on TARA-002; G&A $6.9M (from $4.8M).
Completed IND-enabling studies for TARA-002 in NMIBC; on track to file IND H2 2021 & start Phase 1.
GMP comparability for TARA-002 on track for year-end; seeking FDA alignment on LM trial design.
Appointed Dr. Jane Huang (BeiGene CMO) to Board of Directors in June 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.